The best indicator for 3x Biotech Bull
We backtested 382 indicators across daily, weekly and hourly charts on real 3x Biotech Bull history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Fibonacci Pivots
On the daily chart, this is the strongest risk-adjusted edge we found for 3x Biotech Bull over ~11.1 years — beating buy-and-hold by 45.1% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Fibonacci Pivots ✓ | Daily | 25.1% | 0.67 | -71.6% | 53.4% | 489 | 45.1% |
| 2 | Pivot Points (Standard) ✓ | Daily | 17.7% | 0.58 | -70.8% | 53.9% | 451 | 37.7% |
| 3 | Instantaneous Trendline ✓ | Weekly | 16.6% | 0.55 | -70.7% | 29.2% | 24 | 36.9% |
| 4 | Laguerre RSI ✓ | Daily | 15.5% | 0.54 | -76.3% | 65.0% | 80 | 35.5% |
| 5 | Connors RSI ✓ | Weekly | 13.0% | 0.49 | -71.0% | 62.5% | 32 | 33.3% |
| 6 | Camarilla Pivots ✓ | Daily | 10.4% | 0.48 | -75.5% | 50.2% | 610 | 30.4% |
| 7 | SSL Channel ✓ | Daily | 8.3% | 0.44 | -84.2% | 43.9% | 114 | 28.3% |
| 8 | SMA 20/50 Cross ✓ | Daily | 7.7% | 0.42 | -78.7% | 38.7% | 31 | 27.7% |
| 9 | Net Volume ✓ | Daily | 7.2% | 0.42 | -83.2% | 43.3% | 127 | 27.2% |
| 10 | T3 10/40 Cross ✓ | Daily | 7.9% | 0.42 | -88.3% | 42.4% | 33 | 27.9% |
| 11 | Liquidity Flow Oscillator ✓ | Daily | 7.2% | 0.42 | -83.2% | 43.3% | 127 | 27.2% |
| 12 | Hull MA Trend ✓ | Weekly | 7.7% | 0.42 | -70.6% | 46.4% | 28 | 27.9% |
| 13 | QQE ✓ | Weekly | 1.4% | 0.42 | -97.7% | 39.4% | 33 | 21.7% |
| 14 | Demand Index ✓ | Weekly | 2.7% | 0.42 | -94.7% | 58.8% | 34 | 22.9% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For 3x Biotech Bull, Fibonacci Pivots on the daily timeframe gave the best balance of return and risk in our test. It beat buy-and-hold — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More etf
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.